Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Lijuan Deng(Peking University), Jun Zhu(Peking University), Huilai Zhang(Shanxi Medical University), Wei Zhang(China Southern Power Grid (China)), Zhiming Li(Anhui Medical University), Chunyan Ji(Nanjing University of Chinese Medicine), Haiyan Yang(Zhejiang Cancer Hospital), Yan Li(Zhongyuan University of Technology), Keshu Zhou(Zhengzhou University), Ying Cheng(Jilin Province Tumor Hospital), Renbin Zhao(Kunming University of Science and Technology), Yu Hu(Wuhan Union Hospital), Jianda Hu(Fujian Medical University), Junning Cao(Fudan University Shanghai Cancer Center), Sujun Gao(Jilin University), Hongmei Jing(Peking University), Yongping Song(First Affiliated Hospital of Zhengzhou University), Xin Wang(Shandong Provincial Hospital), Mingzhi Zhang(Chinese Academy of Sciences), Bin Zhang(Guangzhou University of Chinese Medicine), Ting Liu(Chinese PLA General Hospital), Lihong Liu(Hebei Medical University), Xiangyang Zhang(Tsinghua University), Yamin Tian, Wei Xu(Second Military Medical University), Yuqin Song(Peking University), Kaiyang Ding(Anhui Provincial Hospital)
Blood Advances
April 20, 2023
10.1182/bloodadvances.2022009168
Cited by 30

Related Papers

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Targeting the Wnt/β-catenin signaling pathway in cancer
|Journal of Hematology & Oncology|2020|1.4k
Immunoglobulin A Coating Identifies Colitogenic Bacteria in Inflammatory Bowel Disease
|Cell|2014|1.3k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k